One in Six Billion podcast

A podcast about diabetes and genes

With Andrew Hattersley
and Maggie Shepherd

Series 4 episode 6: Hannah Robinson and Nick Thomas. Taking immunotherapy to delay adult-onset Type 1 diabetes

Posted by Design Studio

Released 16 September 2025
Hannah Robinson was the first adult in the UK to be given the new immunotherapy drug Teplizumab, which aims to slow down the development of type 1 diabetes. Hannah had multiple pancreatic autoantibodies and hence is on the path to developing Type 1 diabetes (Series 4 Episode 3). Her consultant, Dr Nick Thomas, arranged 14 consecutive daily hospital visits for her to receive the drug through a drip.

Hannah Robinson was the first adult in the UK to be given the new immunotherapy drug Teplizumab, which aims to slow down the development of type 1 diabetes. Hannah had been found to have multiple pancreatic autoantibodies and hence to be on the path to developing Type 1 diabetes (as she and her diabetes consultant Dr Nick Thomas discussed in Series 4 Episode 3). Nick arranged this new treatment for Hannah at the Royal Devon University Hospital Trust which involved 14 consecutive daily hospital visits for her to receive the drug through a drip.

In this episode, Hannah talks about what it was like to have Teplizumab treatment, especially the challenges of trying to avoid infections while looking after two young children. For Nick arranging immunotherapy was outside his usual work as a diabetes consultant and he reflects on the benefit of involving colleagues who treat patients with blood and kidney diseases with more experience of this type of immune treatment.

For more than a century, type 1 diabetes has meant one thing: a lifetime of insulin therapy. But teplizumab, offers a radically different approach by targeting the immune attack that causes the disease. In type 1 diabetes, the immune system mistakenly destroys the insulin producing cells of the pancreas. Teplizumab works by retraining the immune response, damping down the specific cells that attack the pancreas. Clinical trials show it can delay the onset of diabetes, and the need for insulin, by two to three years with generally mild side effects. To be effective, Teplizumab must be before symptoms arise, while blood sugar levels are still normal. This means these treatments are not an option for people who already have established type 1 diabetes. Fortunately, as in Hannahs case, it is possible to detect the beginnings of the autoimmune attack many years before symptoms show using simple blood tests that measure immune markers called pancreatic autoantibodies.

Teplizumab is now licensed in the UK for children and adults aged 8 years and older with two or more pancreatic autoantibodies and early mild increases in blood glucose (stage 2 type 1 diabetes). This means Teplizumab can now be prescribed in the UK and is being reviewed by NICE to see if it will be funded by the NHS. See https://www.gov.uk/government/news/mhra-approves-teplizumab-to-delay-progression-of-type-1-diabetes

More details about the UK Type 1 diabetes consortium that work on the research behind the prevention of Type 1 diabetes can be found here. https://type1diabetesresearch.org.uk/

Dr Nick Thomas is a lecturer at the University of Exeter as well as being a consultant physician.  He  has a special interest in adult-onset Type 1 diabetes more details about him and his work can be found here. https://experts.exeter.ac.uk/33420-nicholas-thomas